S100A16 in Neurotransmission, Inflammation, and Cell Cycle Progression

Target Name: S100A16

NCBI ID: G140576

S100A16

S100A16 in Neurotransmission, Inflammation, and Cell Cycle Progression

S100A16 (OTTHUMP00000032894) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the S100 family of proteins, which are known for their role in cell signaling and signaling pathways. S100A16 has been identified as a potential drug target and is currently being studied in various clinical trials.

The S100 family of proteins is characterized by the presence of a catalytic center, a transmembrane region, and a cytoplasmic tail. The protein encoded by S100A16 belongs to the S100A family and is characterized by the presence of a catalytic center, a transmembrane region, and a cytoplasmic tail. The catalytic center is the region of the protein that contains the enzyme-active site, which is responsible for catalyzing various chemical reactions.

S100A16 is expressed in various tissues of the body, including the brain, heart, and kidneys. It is also involved in several signaling pathways, including the regulation of cell adhesion, migration, and survival. S100A16 has been shown to play a role in the regulation of neurotransmitter release from neurons and in the modulation of pain perception.

S100A16 has also been shown to be involved in the regulation of inflammation. It has been shown to play a role in the regulation of the immune response and in the modulation of inflammation. S100A16 has been shown to interact with several signaling molecules, including TGF- 尾, NF-kappa-B, and NF-kappa-B.

S100A16 has also been shown to be involved in the regulation of cell cycle progression. It has been shown to play a role in the regulation of cell cycle progression and in the modulation of cell cycle-controlled processes. S100A16 has been shown to interact with several signaling molecules, including CDK4 and p21.

S100A16 has been identified as a potential drug target due to its involvement in several signaling pathways. It is currently being studied in various clinical trials to determine its potential as a drug. S100A16 has been shown to be involved in the regulation of a wide range of physiological processes, including neurotransmission, inflammation, and cell cycle progression. As a result, S100A16 has the potential to be a valuable drug target for the treatment of a wide range of diseases.

Protein Name: S100 Calcium Binding Protein A16

Functions: Calcium-binding protein. Binds one calcium ion per monomer (PubMed:17030513). Can promote differentiation of adipocytes (in vitro) (By similarity). Overexpression in preadipocytes increases their proliferation, enhances adipogenesis and reduces insulin-stimulated glucose uptake (By similarity)

The "S100A16 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about S100A16 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets